These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9825843)

  • 1. p53: prospects for cancer gene therapy.
    Soddu S; Sacchi A
    Cytokines Cell Mol Ther; 1998 Sep; 4(3):177-85. PubMed ID: 9825843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [p53: prospects for gene therapy of cancer].
    Soddu S; Sacchi A
    Clin Ter; 1998; 149(4):289-95. PubMed ID: 9866891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting gene expression to tumor cells with loss of wild-type p53 function.
    Zhu J; Gao B; Zhao J; Balmain A
    Cancer Gene Ther; 2000 Jan; 7(1):4-12. PubMed ID: 10678350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
    Horowitz J
    Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 from basic research to clinical applications.
    Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
    Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis.
    Chang F; Syrjänen S; Kurvinen K; Syrjänen K
    Am J Gastroenterol; 1993 Feb; 88(2):174-86. PubMed ID: 8424417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New transcription factor-based cancer therapy. Gene therapy, cell lysis, reactivation of p53 are the new approaches].
    Wiman KG
    Lakartidningen; 1997 Sep; 94(38):3268-72. PubMed ID: 9379794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classic and novel roles of p53: prospects for anticancer therapy.
    Fuster JJ; Sanz-González SM; Moll UM; Andrés V
    Trends Mol Med; 2007 May; 13(5):192-9. PubMed ID: 17383232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
    Ramondetta L; Mills GB; Burke TW; Wolf JK
    Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
    Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
    Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [p53 as a molecular target for cancer therapy].
    Ishioka C; Osada M; Gamo M; Kanamaru R
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2207-12. PubMed ID: 9422063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer.
    Rizk NP; Chang MY; El Kouri C; Seth P; Kaiser LR; Albelda SM; Amin KM
    Cancer Gene Ther; 1999; 6(4):291-301. PubMed ID: 10419047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 tumor suppressor gene therapy for cancer.
    Nielsen LL; Maneval DC
    Cancer Gene Ther; 1998; 5(1):52-63. PubMed ID: 9476967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
    Kim E; Giese A; Deppert W
    Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient translocation and apoptosis induction by adenovirus encoded VP22-p53 fusion protein in human tumor cells in vitro.
    Roy I; Holle L; Song W; Holle E; Wagner T; Yu X
    Anticancer Res; 2002; 22(6A):3185-9. PubMed ID: 12530063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy.
    Resnick-Silverman L; Manfredi JJ
    J Cell Biochem; 2006 Oct; 99(3):679-89. PubMed ID: 16676359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The p53 tumour suppressor gene.
    Steele RJ; Thompson AM; Hall PA; Lane DP
    Br J Surg; 1998 Nov; 85(11):1460-7. PubMed ID: 9823903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.